Ipsilateral breast carcinoma following treatment for primary breast lymphoma

Onkologie. 2007 Mar;30(3):134-6. doi: 10.1159/000099143. Epub 2007 Feb 13.

Abstract

Background: The breast is an unusual site for primary non-Hodgkin's lymphoma. Carcinoma in the same breast after treatment for lymphoma poses therapeutic challenges, but there is only 1 case report in Japanese, which describes this occurrence.

Patient and methods: A 59-year-old woman was diagnosed with infiltrating ductal carcinoma of the breast after receiving doxorubicinand vincristine-based chemotherapy for ipsilateral primary large cell breast lymphoma. The cancer was of high grade histology, with immunohistochemistry staining 3+ positive for HER2/neu.

Results: After lumpectomy and sentinel node biopsy, adjuvant paclitaxel without anthracyclines was given but had to be stopped early because of neurotoxicity. Radiotherapy to the breast was administered, and a 1-year course of trastuzumab was planned.

Conclusion: Breast cancer can occur after breast lymphoma. For primary breast lymphoma, cumulative doses of cardiotoxic and neurotoxic drugs should be limited to 3-4 cycles of chemotherapy, using treatment protocols for stage I-II large cell lymphoma. Consolidation radiotherapy should be considered at a dose curative for microscopic breast cancer.

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biomarkers, Tumor / analysis
  • Breast / pathology
  • Carcinoma, Ductal / diagnosis*
  • Carcinoma, Ductal / pathology
  • Carcinoma, Ductal / therapy*
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Lymphoma, B-Cell / diagnosis*
  • Lymphoma, B-Cell / pathology
  • Lymphoma, B-Cell / therapy*
  • Lymphoma, Large B-Cell, Diffuse / diagnosis*
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Lymphoma, Large B-Cell, Diffuse / therapy*
  • Mastectomy, Segmental
  • Middle Aged
  • Neoplasms, Second Primary / diagnosis*
  • Neoplasms, Second Primary / pathology
  • Neoplasms, Second Primary / therapy*
  • Radiotherapy, Adjuvant
  • Receptor, ErbB-2 / analysis
  • Retreatment

Substances

  • Biomarkers, Tumor
  • Receptor, ErbB-2